Cargando…

Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-x(L) inhibitors on human ovarian carcinoma cells

The inhibition of two major anti-apoptotic proteins, Bcl-x(L) and Mcl-1, appears essential to destroy chemoresistant cancer cells. We have studied their concomitant inhibition, using ABT 737 or siRNA targeting XL1 and citrate, a molecule which reduces the expression level of Mcl-1. Two cisplatin-che...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lincet, Hubert, Kafara, Perrine, Giffard, Florence, Abeilard-Lemoisson, Edwige, Duval, Maryline, Louis, Marie-Hélène, Poulain, Laurent, Icard, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851866/ https://www.ncbi.nlm.nih.gov/pubmed/24103422 http://dx.doi.org/10.1186/1757-2215-6-72

Ejemplares similares

Lipoic acid decreases Mcl-1, Bcl-x(L) and up regulates Bim on ovarian carcinoma cells leading to cell death
por: Kafara, Perrine, et al.
Publicado: (2015)

Sensitization of ovarian carcinoma cells to Bcl-x(L)-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family
por: Tomasina, Julie, et al.
Publicado: (2013)

Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-x(L) strategies through Mcl-1 down-regulation
por: Bonnefond, Marie-Laure, et al.
Publicado: (2015)

Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-Bclx(L) strategies through Mcl-1 down-regulation
por: Bonnefond, Marie-Laure, et al.
Publicado: (2018)

Citrate targets FBPase and constitutes an emerging novel approach for cancer therapy
por: Icard, Philippe, et al.
Publicado: (2018)

Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update
por: Icard, Philippe, et al.
Publicado: (2021)

miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-X(L) and EGFR leading to BIM activation
por: Denoyelle, C, et al.
Publicado: (2014)

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020)

A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers
por: Aide, Nicolas, et al.
Publicado: (2021)

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma
por: Thorel, Lucie, et al.
Publicado: (2023)

The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response
por: Icard, Philippe, et al.
Publicado: (2021)

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
por: Seiller, Carolane, et al.
Publicado: (2020)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2020)

The lncRNA ‘UCA1’ modulates the response to chemotherapy of ovarian cancer through direct binding to miR‐27a‐5p and control of UBE2N levels
por: Wambecke, Anaïs, et al.
Publicado: (2021)

Cyclic Marinopyrrole Derivatives as Disruptors of Mcl-1 and Bcl-x(L) Binding to Bim
por: Cheng, Chunwei, et al.
Publicado: (2014)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
por: Dalafave, D.S., et al.
Publicado: (2010)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019)

Selective Affimers Recognise the BCL‐2 Family Proteins BCL‐x(L) and MCL‐1 through Noncanonical Structural Motifs
por: Miles, Jennifer A., et al.
Publicado: (2020)

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
por: Melvold, Katrine, et al.
Publicado: (2021)

Lipoic acid decreases breast cancer cell proliferation by inhibiting IGF-1R via furin downregulation
por: Farhat, Diana, et al.
Publicado: (2020)

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
por: Booher, Robert N., et al.
Publicado: (2014)

Computational design of an apoptogenic protein that binds BCL-xL and MCL-1 simultaneously and potently
por: Kim, Seonghoon, et al.
Publicado: (2022)

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X(L) expression
por: Yasuda, Yuto, et al.
Publicado: (2020)

Atelocollagen-mediated in vivo siRNA transfection in ovarian carcinoma is influenced by tumor site, siRNA target and administration route
por: Meryet-Figuière, Matthieu, et al.
Publicado: (2017)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1
por: Ow, Thomas J., et al.
Publicado: (2019)

Anti-apoptotic Bcl-X(L) but not Mcl-1 contributes to protection against virus-induced apoptosis
por: Ohmer, Michaela, et al.
Publicado: (2016)

ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins
por: Alcon, Clara, et al.
Publicado: (2021)

Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1
por: Robinson, Edward J., et al.
Publicado: (2018)

A direct comparison of selective BH3-mimetics reveals BCL-X(L), BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
por: Bierbrauer, Annika, et al.
Publicado: (2020)

The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition
por: Peddaboina, Chander, et al.
Publicado: (2012)

MCL-1, BCL-X(L) and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment
por: Hartman, Mariusz L., et al.
Publicado: (2015)

Targeting MCL-1/BCL-X(L) Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
por: Lin, Kevin H., et al.
Publicado: (2016)

Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors
por: Dolivet, Enora, et al.
Publicado: (2023)

Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1
por: Mena, Salvador, et al.
Publicado: (2012)

Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
por: Golla, Carolin, et al.
Publicado: (2021)

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2
Publicado: (1995)

Combined reduction in the expression of MCL-1 and BCL-2 reduces organismal size in mice
por: Ke, Francine, et al.
Publicado: (2020)

Correction to: Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1
por: Robinson, Edward J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_epg28v75b67gkb5sdgvbh14qua